BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, Turchin A. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526-534. [PMID: 23546564 DOI: 10.7326/0003-4819-158-7-201304020-00004] [Cited by in Crossref: 328] [Cited by in F6Publishing: 335] [Article Influence: 36.4] [Reference Citation Analysis]
Number Citing Articles
1 Razavi AC, Mehta A, Sperling LS. Statin therapy for the primary prevention ofatherosclerotic cardiovascular disease: Pros. Atherosclerosis 2022:S0021-9150(22)01345-4. [PMID: 35945050 DOI: 10.1016/j.atherosclerosis.2022.07.004] [Reference Citation Analysis]
2 Orringer CE, Grant JK, Tokgozoglu L. A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms. Curr Atheroscler Rep 2022. [PMID: 36001213 DOI: 10.1007/s11883-022-01059-x] [Reference Citation Analysis]
3 Golder S, Weissenbacher D, O’connor K, Hennessy S, Gross R, Hernandez GG. Patient-Reported Reasons for Switching or Discontinuing Statin Therapy: A Mixed Methods Study Using Social Media. Drug Saf. [DOI: 10.1007/s40264-022-01212-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lane D, Beishon L, Sharma V, Salim F, Sze S, Timmins MA, Robinson T, Eveson D, Mistri A, Patel P, Gupta P. High non-adherence rates to secondary prevention by chemical adherence testing in patients with TIA. J Stroke Cerebrovasc Dis 2022;31:106665. [PMID: 35901588 DOI: 10.1016/j.jstrokecerebrovasdis.2022.106665] [Reference Citation Analysis]
5 Petry NJ, Baye JF, Frear S, Jacobsen K, Massmann A, Schultz A, Heukelom JV, Christensen K. Progression of precision statin prescribing for reduction of statin-associated muscle symptoms. Pharmacogenomics 2022. [PMID: 35775396 DOI: 10.2217/pgs-2022-0055] [Reference Citation Analysis]
6 Krishnamurthy A, Bradley C, Ascunce R, Kim SM. SAMSON and the Nocebo Effect: Management of Statin Intolerance. Curr Cardiol Rep 2022. [PMID: 35759168 DOI: 10.1007/s11886-022-01729-x] [Reference Citation Analysis]
7 Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, Dixon DL, Maki KC. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol 2022:S1933-2874(22)00167-2. [PMID: 35718660 DOI: 10.1016/j.jacl.2022.05.068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Parham JS, Goldberg AC. Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know. Curr Atheroscler Rep 2022. [PMID: 35666408 DOI: 10.1007/s11883-022-01036-4] [Reference Citation Analysis]
9 Tudor K, Brooks J, Howick J, Fox R, Aveyard P. Unblinded and Blinded N-of-1 Trials Versus Usual Care: A Randomized Controlled Trial to Increase Statin Uptake in Primary Care. Circ Cardiovasc Qual Outcomes 2022;15:e007793. [PMID: 35698974 DOI: 10.1161/CIRCOUTCOMES.120.007793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Desai NR, Campbell C, Electricwala B, Petrou M, Trueman D, Woodcock F, Cristino J. Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis. Am J Cardiovasc Drugs 2022. [PMID: 35595929 DOI: 10.1007/s40256-022-00534-9] [Reference Citation Analysis]
11 Khatib R, Khan M, Barrowcliff A, Ikongo E, Burton C, Mansfield M, Hall A. Innovative, centralised, multidisciplinary medicines optimisation clinic for PCSK9 inhibitors. Open Heart 2022;9:e001931. [PMID: 35393352 DOI: 10.1136/openhrt-2021-001931] [Reference Citation Analysis]
12 Hong JH, Jeon U, Shin W, Kim W, Seong K, Park S, Kim H, Chung J, Choi J. A Paradigm Shift in Dyslipidemia Management in Primary Care: A 12-Month Cohort Study. Clinical Therapeutics 2022. [DOI: 10.1016/j.clinthera.2022.03.004] [Reference Citation Analysis]
13 Penson PE, Bruckert E, Marais D, Reiner Ž, Pirro M, Sahebkar A, Bajraktari G, Mirrakhimov E, Rizzo M, Mikhailidis DP, Sachinidis A, Gaita D, Latkovskis G, Mazidi M, Toth PP, Pella D, Alnouri F, Postadzhiyan A, Yeh H, Mancini GJ, von Haehling S, Banach M, Acosta J, Al‐khnifsawi M, Alnouri F, Amar F, Atanasov AG, Bajraktari G, Banach M, Bhaskar S, Bytyçi I, Bjelakovic B, Bruckert E, Cafferata A, Ceska R, Cicero AF, Collet X, Daccord M, Descamps O, Djuric D, Durst R, Ezhov MV, Fras Z, Gaita D, Hernandez AV, Jones SR, Jozwiak J, Kakauridze N, Kallel A, Katsiki N, Khera A, Kostner K, Kubilius R, Latkovskis G, Mancini GJ, Marais AD, Martin SS, Martinez JA, Mazidi M, Mikhailidis DP, Mirrakhimov E, Miserez AR, Mitchenko O, Mitkovskaya NP, Moriarty PM, Nabavi SM, Nair D, Panagiotakos DB, Paragh G, Pella D, Penson PE, Petrulioniene Z, Pirro M, Postadzhiyan A, Puri R, Reda A, Reiner Ž, Radenkovic D, Rakowski M, Riadh J, Richter D, Rizzo M, Ruscica M, Sahebkar A, Sattar N, Serban M, Shehab AM, Shek AB, Sirtori CR, Stefanutti C, Tomasik T, Toth PP, Viigimaa M, Valdivielso P, Vinereanu D, Vohnout B, von Haehling S, Vrablik M, Wong ND, Yeh H, Zhisheng J, Zirlik A; International Lipid Expert Panel (ILEP). Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). J cachexia sarcopenia muscle 2022;13:1596-622. [DOI: 10.1002/jcsm.12960] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
14 Alkabbani W, Pelletier R, Beazely MA, Labib Y, Quan B, Gamble JM. Drug-Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data. Drug Saf 2022. [PMID: 35247195 DOI: 10.1007/s40264-022-01166-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Laufs U, Ballantyne CM, Banach M, Bays H, Catapano AL, Duell PB, Goldberg AC, Gotto AM, Leiter LA, Ray KK, Bloedon LT, Macdougall D, Zhang Y, Mancini GBJ. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. Journal of Clinical Lipidology 2022. [DOI: 10.1016/j.jacl.2022.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Rossi M, Fabris E, Barbisan D, Massa L, Sinagra G. Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice. Am J Cardiovasc Drugs 2022;22:141-55. [PMID: 34514551 DOI: 10.1007/s40256-021-00497-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Goga A, Stoffel M. Therapeutic RNA-silencing oligonucleotides in metabolic diseases. Nat Rev Drug Discov 2022. [PMID: 35210608 DOI: 10.1038/s41573-022-00407-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lin Y, Parco C, Karathanos A, Krieger T, Schulze V, Chernyak N, Icks A, Kelm M, Brockmeyer M, Wolff G. Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis. BMJ Open 2022;12:e048893. [PMID: 35210334 DOI: 10.1136/bmjopen-2021-048893] [Reference Citation Analysis]
19 Farzad M, Jafari S, Hesary FB, Chahkandak FH, Kazemi T, Bizhaem SK, Sharifi F. Statin treatment and serum low-density lipoprotein (LDL) level in the Birjand elderly dwellers: Birjand Longitudinal Aging Study (BLAS) Wave3. J Diabetes Metab Disord. [DOI: 10.1007/s40200-021-00950-9] [Reference Citation Analysis]
20 Nishikido T, Ray KK. The power of lipid registries for cardiovascular disease prevention. Curr Opin Lipidol 2021;32:342-8. [PMID: 34561312 DOI: 10.1097/MOL.0000000000000783] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Talic S, Marquina C, Zomer E, Asenso RO, Petrova M, Vargas-Torres S, Abushana D, Wolfe R, Lybrand S, Thomson D, Stratton G, Liew D, Ademi Z. Attainment of low-density lipoprotein cholesterol goals in statin treated patients: real-world evidence from Australia. Curr Probl Cardiol 2021;:101068. [PMID: 34818528 DOI: 10.1016/j.cpcardiol.2021.101068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Belch JJF, Brodmann M, Baumgartner I, Binder CJ, Casula M, Heiss C, Kahan T, Parini P, Poredos P, Catapano AL, Tokgözoğlu L. Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement. Atherosclerosis 2021;338:55-63. [PMID: 34763902 DOI: 10.1016/j.atherosclerosis.2021.09.022] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
23 Belch JJF, Brodmann M, Baumgartner I, Binder CJ, Casula M, Heiss C, Kahan T, Parini P, Poredos P, Catapano AL, Tokgözoğlu L. Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. Vasa 2021;50:401-11. [PMID: 34743585 DOI: 10.1024/0301-1526/a000969] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Dephillips C, Parikh PB, Stevens GA. Dyslipidemia: Current Therapies and Strategies to Overcome Barriers for Use. The Journal for Nurse Practitioners 2021;17:1167-73. [DOI: 10.1016/j.nurpra.2021.08.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Brunette CA, Dong OM, Vassy JL, Danowski ME, Alexander N, Antwi AA, Christensen KD. A Cost-Consequence Analysis of Preemptive SLCO1B1 Testing for Statin Myopathy Risk Compared to Usual Care. J Pers Med 2021;11:1123. [PMID: 34834475 DOI: 10.3390/jpm11111123] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Grundy SM, Vega GL. Statin Intolerance and Noncompliance: An Empiric Approach. Am J Med 2021:S0002-9343(21)00644-6. [PMID: 34717898 DOI: 10.1016/j.amjmed.2021.09.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Jia X, Lee MT, Ramsey DJ, Mahtta D, Akeroyd JM, Turchin A, Navar AM, Matheny ME, Gobbel G, Stone NJ, Nambi V, Ballantyne CM, Petersen LA, Virani SS. Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the veteran's affairs healthcare system. J Clin Lipidol 2021:S1933-2874(21)00249-X. [PMID: 34666951 DOI: 10.1016/j.jacl.2021.09.050] [Reference Citation Analysis]
28 Berman AN, Biery DW, Ginder C, Hulme OL, Marcusa D, Leiva O, Wu WY, Cardin N, Hainer J, Bhatt DL, Di Carli MF, Turchin A, Blankstein R. Natural language processing for the assessment of cardiovascular disease comorbidities: The cardio-Canary comorbidity project. Clin Cardiol 2021. [PMID: 34347314 DOI: 10.1002/clc.23687] [Reference Citation Analysis]
29 Abo-Zalam HB, El-Denshary ES, Abdelsalam RM, Khalil IA, Khattab MM, Hamzawy MA. Therapeutic advancement of simvastatin-loaded solid lipid nanoparticles (SV-SLNs) in treatment of hyperlipidemia and attenuating hepatotoxicity, myopathy and apoptosis: Comprehensive study. Biomed Pharmacother 2021;139:111494. [PMID: 34243595 DOI: 10.1016/j.biopha.2021.111494] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Brunette CA, Vassy JL. The role of SLCO1B1 genotyping in lowering cardiovascular risk. Pharmacogenomics 2021;22:649-56. [PMID: 34196599 DOI: 10.2217/pgs-2021-0075] [Reference Citation Analysis]
31 de Beer R, Outhoff K, Phulukdaree A, Soma P. Prevalence of SLCO1B1 single nucleotide variations and their association with hypercholesterolaemia in hypercholesterolemic patients in Gauteng, South Africa. Xenobiotica 2021;51:949-59. [PMID: 34154510 DOI: 10.1080/00498254.2021.1945165] [Reference Citation Analysis]
32 Kim EJ, Wierzbicki AS. Investigating raised creatine kinase. BMJ 2021;373:n1486. [PMID: 34162592 DOI: 10.1136/bmj.n1486] [Reference Citation Analysis]
33 Davis JW, Weller SC. Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients. BMJ Open 2021;11:e043714. [PMID: 34130955 DOI: 10.1136/bmjopen-2020-043714] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
34 Insani WN, Whittlesea C, Alwafi H, Man KKC, Chapman S, Wei L. Prevalence of adverse drug reactions in the primary care setting: A systematic review and meta-analysis. PLoS One 2021;16:e0252161. [PMID: 34038474 DOI: 10.1371/journal.pone.0252161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
35 Jhaveri A, Sibley RA, Spatz ES, Dodson J. Aspirin, Statins, and Primary Prevention: Opportunities for Shared Decision Making in the Face of Uncertainty. Curr Cardiol Rep 2021;23:67. [PMID: 33961154 DOI: 10.1007/s11886-021-01499-y] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
36 Vázquez-Manjarrez N, Guevara-Cruz M, Flores-López A, Pichardo-Ontiveros E, Tovar AR, Torres N. Effect of a dietary intervention with functional foods on LDL-C concentrations and lipoprotein subclasses in overweight subjects with hypercholesterolemia: Results of a controlled trial. Clin Nutr 2021;40:2527-34. [PMID: 33932799 DOI: 10.1016/j.clnu.2021.02.048] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Mostaza JM, Lahoz C. Main barriers in the management of dyslipidaemias: Intolerants. Clin Investig Arterioscler 2021;33 Suppl 1:40-5. [PMID: 33966812 DOI: 10.1016/j.arteri.2020.12.003] [Reference Citation Analysis]
38 Beshir SA, Hussain N, Elnor AA, Said ASA. Umbrella Review on Non-Statin Lipid-Lowering Therapy. J Cardiovasc Pharmacol Ther 2021;26:437-52. [PMID: 33836639 DOI: 10.1177/10742484211002943] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
39 Ryou IS, Chang J, Son JS, Ko A, Choi S, Kim K, Kim SM, Park SM. Association between CVDs and initiation and adherence to statin treatment in patients with newly diagnosed hypercholesterolaemia: a retrospective cohort study. BMJ Open 2021;11:e045375. [PMID: 33827840 DOI: 10.1136/bmjopen-2020-045375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
40 Guerrero-Bonmatty R, Gil-Fernández G, Rodríguez-Velasco FJ, Espadaler-Mazo J. A Combination of Lactoplantibacillus plantarum Strains CECT7527, CECT7528, and CECT7529 Plus Monacolin K Reduces Blood Cholesterol: Results from a Randomized, Double-Blind, Placebo-Controlled Study. Nutrients 2021;13:1206. [PMID: 33917503 DOI: 10.3390/nu13041206] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Laufs U, Isermann B. Statin intolerance: myths and facts. Eur Heart J 2020;41:3343-5. [PMID: 32702749 DOI: 10.1093/eurheartj/ehaa582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
42 Herrett E, Williamson E, Brack K, Perkins A, Thayne A, Shakur-Still H, Roberts I, Prowse D, Beaumont D, Jamal Z, Goldacre B, van Staa T, MacDonald TM, Armitage J, Moore M, Hoffman M, Smeeth L. The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs. Health Technol Assess 2021;25:1-62. [PMID: 33709907 DOI: 10.3310/hta25160] [Reference Citation Analysis]
43 Newman CB, Blaha MJ, Boord JB, Cariou B, Chait A, Fein HG, Ginsberg HN, Goldberg IJ, Murad MH, Subramanian S, Tannock LR. Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2020;105:dgaa674. [PMID: 32951056 DOI: 10.1210/clinem/dgaa674] [Cited by in Crossref: 11] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
44 Herrett E, Williamson E, Brack K, Beaumont D, Perkins A, Thayne A, Shakur-Still H, Roberts I, Prowse D, Goldacre B, van Staa T, MacDonald TM, Armitage J, Wimborne J, Melrose P, Singh J, Brooks L, Moore M, Hoffman M, Smeeth L; StatinWISE Trial Group. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ 2021;372:n135. [PMID: 33627334 DOI: 10.1136/bmj.n135] [Cited by in Crossref: 15] [Cited by in F6Publishing: 39] [Article Influence: 15.0] [Reference Citation Analysis]
45 Camerino GM, Tarantino N, Canfora I, De Bellis M, Musumeci O, Pierno S. Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence. Int J Mol Sci 2021;22:2070. [PMID: 33669797 DOI: 10.3390/ijms22042070] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
46 Yourman LC, Cenzer IS, Boscardin WJ, Nguyen BT, Smith AK, Schonberg MA, Schoenborn NL, Widera EW, Orkaby A, Rodriguez A, Lee SJ. Evaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis. JAMA Intern Med 2021;181:179-85. [PMID: 33196766 DOI: 10.1001/jamainternmed.2020.6084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
47 Sinning D, Landmesser U. [New Lipid-lowering Agents]. Dtsch Med Wochenschr 2021;146:92-101. [PMID: 33465805 DOI: 10.1055/a-1199-8496] [Reference Citation Analysis]
48 Park HH, Kim JH, Yoon D, Lee H, Shin JY. Gender differences in the adverse events associated with cardiovascular drugs in a spontaneous reporting system in South Korea. Int J Clin Pharm 2021;43:1036-44. [PMID: 33439426 DOI: 10.1007/s11096-020-01212-z] [Reference Citation Analysis]
49 Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41:255-323. [PMID: 31497854 DOI: 10.1093/eurheartj/ehz486] [Cited by in Crossref: 925] [Cited by in F6Publishing: 1286] [Article Influence: 925.0] [Reference Citation Analysis]
50 Avram VF, Chamkha I, Åsander-Frostner E, Ehinger JK, Timar RZ, Hansson MJ, Muntean DM, Elmér E. Cell-Permeable Succinate Rescues Mitochondrial Respiration in Cellular Models of Statin Toxicity. Int J Mol Sci 2021;22:E424. [PMID: 33401621 DOI: 10.3390/ijms22010424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
51 Patel PN, Giugliano RP. Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease. Glob Cardiol Sci Pract 2020;2020:e202039. [PMID: 33598499 DOI: 10.21542/gcsp.2020.39] [Reference Citation Analysis]
52 Casula M, Gazzotti M, Bonaiti F, OImastroni E, Arca M, Averna M, Zambon A, Catapano AL; PROSISA Study Group. Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. J Intern Med 2021;290:116-28. [PMID: 33259671 DOI: 10.1111/joim.13219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
53 Kosmas CE, Skavdis A, Sourlas A, Papakonstantinou EJ, Peña Genao E, Echavarria Uceta R, Guzman E. Safety and Tolerability of PCSK9 Inhibitors: Current Insights. Clin Pharmacol 2020;12:191-202. [PMID: 33335431 DOI: 10.2147/CPAA.S288831] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
54 Wijekoon N, Wijekoon S, Bulugahapitiya U, Pathirana N, Wickramasinghe M, Paranavitane S, Kottage A, Wijayawardena S, Karunarathne M, Samarasinghe M, Sumanadasa S, Herath Y. Tolerability and effectiveness of every-other-day atorvastatin compared to daily atorvastatin in patients with muscle symptoms: A randomized controlled clinical trial. Contemp Clin Trials Commun 2020;20:100685. [PMID: 33319120 DOI: 10.1016/j.conctc.2020.100685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Bath J, Lawrence PF, Neal D, Zhao Y, Smith JB, Beck AW, Conte M, Schermerhorn M, Woo K. Endovascular interventions for claudication do not meet minimum standards for the Society for Vascular Surgery efficacy guidelines. J Vasc Surg 2021;73:1693-1700.e3. [PMID: 33253869 DOI: 10.1016/j.jvs.2020.10.067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
56 Cheon B, Kumar A, Tsalatsanis A, Cowart K, Magness RR, Tipparaju SM, Carris NW. Impact of Metformin on Statin Persistence: a Post Hoc Analysis of a Large Randomized Controlled Trial. J Gen Intern Med 2022;37:277-9. [PMID: 33210192 DOI: 10.1007/s11606-020-06344-6] [Reference Citation Analysis]
57 Ahmed ST, Akeroyd JM, Mahtta D, Street R, Slagle J, Navar AM, Stone NJ, Ballantyne CM, Petersen LA, Virani SS. Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects. J Am Heart Assoc 2020;9:e017915. [PMID: 33170055 DOI: 10.1161/JAHA.120.017915] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
58 Moon J, Cohen Sedgh R, Jackevicius CA. Examining the Nocebo Effect of Statins Through Statin Adverse Events Reported in the Food and Drug Administration Adverse Event Reporting System. Circ Cardiovasc Qual Outcomes 2021;14:e007480. [PMID: 33161769 DOI: 10.1161/CIRCOUTCOMES.120.007480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
59 Khan SA, Naz A, Qamar Masood M, Shah R. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. Am J Cardiol 2020;134:69-73. [PMID: 32892993 DOI: 10.1016/j.amjcard.2020.08.018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
60 Sinning D, Landmesser U. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran). Curr Cardiol Rep 2020;22:176. [PMID: 33089390 DOI: 10.1007/s11886-020-01427-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
61 Gurha N, Rehan HS, Yadav M, Gupta LK. Association of statin induced reduction in serum coenzyme Q10 level and conduction deficits in motor and sensory nerves: An observational cross-sectional study. Clinical Neurology and Neurosurgery 2020;196:106046. [DOI: 10.1016/j.clineuro.2020.106046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
62 Sbrana F, Dal Pino B, Bigazzi F, Ripoli A, Passino C, Gabutti A, Pasanisi EM, Petersen C, Valleggi A, Todiere G, Barison A, Giannoni A, Panchetti L, Becherini F, Pianelli M, Luciani R, Sampietro T. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else? European Journal of Preventive Cardiology 2017;24:1528-31. [DOI: 10.1177/2047487317712419] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
63 Kam N, Perera K, Zomer E, Liew D, Ademi Z. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis. PharmacoEconomics 2020;38:1007-20. [DOI: 10.1007/s40273-020-00948-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
64 Spahillari A, Zhu J, Ferket BS, Hunink MGM, Carr JJ, Terry JG, Nelson C, Mwasongwe S, Mentz RJ, O'Brien EC, Correa A, Shah RV, Murthy VL, Pandya A. Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals. JAMA Cardiol 2020;5:871-80. [PMID: 32401264 DOI: 10.1001/jamacardio.2020.1240] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
65 Li JJ, Liu HH, Wu NQ, Yeo KK, Tan K, Ako J, Krittayaphong R, Tan RS, Aylward PE, Baek SH, Dalal J, Fong AYY, Li YH, O'Brien RC, Lim TSE, Koh SYN, Scherer DJ, Tada H, Kang V, Butters J, Nicholls SJ. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. Expert Opin Drug Metab Toxicol 2020;16:837-51. [PMID: 32729743 DOI: 10.1080/17425255.2020.1802426] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
66 Hickson RP, Robinson JG, Annis IE, Killeya-Jones LA, Fang G. It's Not Too Late to Improve Statin Adherence: Association Between Changes in Statin Adherence from Before to After Acute Myocardial Infarction and All-Cause Mortality. J Am Heart Assoc 2019;8:e011378. [PMID: 30929542 DOI: 10.1161/JAHA.118.011378] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
67 Faasse K, Huynh A, Pearson S, Geers AL, Helfer SG, Colagiuri B. The Influence of Side Effect Information Framing on Nocebo Effects. Ann Behav Med 2019;53:621-9. [PMID: 30204841 DOI: 10.1093/abm/kay071] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
68 Kohli-Lynch CN, Bellows BK, Thanassoulis G, Zhang Y, Pletcher MJ, Vittinghoff E, Pencina MJ, Kazi D, Sniderman AD, Moran AE. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk. JAMA Cardiol 2019;4:969-77. [PMID: 31461121 DOI: 10.1001/jamacardio.2019.2851] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
69 Soran H, France M, Adam S, Iqbal Z, Ho JH, Durrington PN. Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance. Atherosclerosis 2020;306:33-40. [PMID: 32683135 DOI: 10.1016/j.atherosclerosis.2020.06.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
70 Tanner RM, Colantonio LD, Kilgore ML, Mefford MT, Chachappan DT, Mues KE, Safford MM, Rosenson RS, Muntner P. Low-density lipoprotein cholesterol levels among individuals experiencing statin-associated symptoms: Data from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. J Clin Lipidol 2020;14:720-9. [PMID: 32680814 DOI: 10.1016/j.jacl.2020.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Dai L, Zuo Y, You Q, Zeng H, Cao S. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: A systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol 2021;28:825-33. [PMID: 34298558 DOI: 10.1177/2047487320930585] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
72 Kim EJ, Wierzbicki AS. The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. Ther Adv Chronic Dis 2020;11:2040622320924569. [PMID: 32537117 DOI: 10.1177/2040622320924569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
73 Tiniakou E. Statin-Associated Autoimmune Myopathy: Current Perspectives. Ther Clin Risk Manag 2020;16:483-92. [PMID: 32581543 DOI: 10.2147/TCRM.S197941] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
74 Millar DA, Bowles S, Windvogel SL, Louw J, Muller CJF. Effect of Rooibos (Aspalathus linearis) extract on atorvastatin-induced toxicity in C3A liver cells. J Cell Physiol 2020;235:9487-96. [PMID: 32458430 DOI: 10.1002/jcp.29756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
75 . Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD). Revista Española de Cardiología 2020;73:404.e1-404.e59. [DOI: 10.1016/j.recesp.2019.11.024] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Harris DE, Lacey A, Akbari A, Torabi F, Smith D, Jenkins G, Obaid D, Chase A, Gravenor M, Halcox J. Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: A population-level observational cohort study. Eur J Prev Cardiol 2021;28:854-61. [PMID: 34298561 DOI: 10.1177/2047487320914115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
77 Jeong HY, Lee SY, Kim SH, Kim J. Long-Term Benefit and Withdrawal Effect of Statins After Percutaneous Coronary Intervention: A Nationwide Population-Based Cohort Study. Patient Prefer Adherence 2020;14:717-24. [PMID: 32308376 DOI: 10.2147/PPA.S245324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
78 Shoaf SE, Ouyang J, Sergeyeva O, Estilo A, Li H, Leung D. A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials. Clin J Am Soc Nephrol 2020;15:643-50. [PMID: 32241780 DOI: 10.2215/CJN.08170719] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
79 Tudor K, Brooks J, Howick J, Fox R, Aveyard P. Tackling statin intolerance with n-of-1 trials (TaSINI) in primary care: protocol for a feasibility randomised trial to increase statin adherence. BMJ Open 2020;10:e033070. [PMID: 32051312 DOI: 10.1136/bmjopen-2019-033070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
80 Pan SW, Yen YF, Feng JY, Chuang PH, Su VY, Kou YR, Su WJ, Chan YJ. Opposite effects of statins on the risk of tuberculosis and herpes zoster in patients with diabetes: A population-based cohort study. Br J Clin Pharmacol 2020;86:569-79. [PMID: 31633826 DOI: 10.1111/bcp.14142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
81 Rashid S. Lower LDL is better – can this be achieved with CETP inhibition therapy? Expert Review of Cardiovascular Therapy 2020;18:1-5. [DOI: 10.1080/14779072.2020.1715797] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
82 Zhou Z, Albarqouni L, Curtis AJ, Breslin M, Nelson M. The Safety and Tolerability of Statin Therapy in Primary Prevention in Older Adults: A Systematic Review and Meta-analysis. Drugs Aging 2020;37:175-85. [DOI: 10.1007/s40266-019-00736-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
83 McConachie SM, Giuliano CA, Mohammad I, Kale-Pradhan PB. Adverse drug reactions in drug information databases: does presentation affect interpretation? J Med Libr Assoc 2020;108:76-83. [PMID: 31897054 DOI: 10.5195/jmla.2020.748] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Colantonio LD, Rosenson RS, Deng L, Monda KL, Dai Y, Farkouh ME, Safford MM, Philip K, Mues KE, Muntner P. Adherence to Statin Therapy Among US Adults Between 2007 and 2014. J Am Heart Assoc 2019;8:e010376. [PMID: 30616455 DOI: 10.1161/JAHA.118.010376] [Cited by in Crossref: 51] [Cited by in F6Publishing: 58] [Article Influence: 25.5] [Reference Citation Analysis]
85 Dong OM, Wheeler SB, Cruden G, Lee CR, Voora D, Dusetzina SB, Wiltshire T. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. Value in Health 2020;23:61-73. [DOI: 10.1016/j.jval.2019.08.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
86 Turner RM, Pirmohamed M. Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. J Clin Med 2019;9:E22. [PMID: 31861911 DOI: 10.3390/jcm9010022] [Cited by in Crossref: 54] [Cited by in F6Publishing: 63] [Article Influence: 18.0] [Reference Citation Analysis]
87 Aslam M, Troidl C, Tanislav C, Rohrbach S, Gündüz D, Hamm CW. Inhibition of Protein Prenylation of GTPases Alters Endothelial Barrier Function. Int J Mol Sci 2019;21:E2. [PMID: 31861297 DOI: 10.3390/ijms21010002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
88 Brooks DC, Schindler JL. Management of Hyperlipidemia After Stroke. Curr Treat Options Cardiovasc Med 2019;21:93. [PMID: 31840196 DOI: 10.1007/s11936-019-0774-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
89 Heigl F, Pflederer T, Klingel R, Hettich R, Lotz N, Reeg H, Schettler VJJ, Roeseler E, Grützmacher P, Hohenstein B, Julius U. Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy? Atheroscler Suppl 2019;40:23-9. [PMID: 31818446 DOI: 10.1016/j.atherosclerosissup.2019.08.038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
90 Panozzo CA, Curtis LH, Marshall J, Fine L, Wells BL, Brown JS, Haynes K, Pawloski PA, Hernandez AF, Malek S, Syat B, Platt R. Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018. PLoS One 2019;14:e0223515. [PMID: 31805056 DOI: 10.1371/journal.pone.0223515] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
91 Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK; American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol 2019;39:e38-81. [PMID: 30580575 DOI: 10.1161/ATV.0000000000000073] [Cited by in Crossref: 170] [Cited by in F6Publishing: 229] [Article Influence: 56.7] [Reference Citation Analysis]
92 Nishikido T, Ray KK. Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges. Br J Pharmacol 2021;178:2168-85. [PMID: 31465540 DOI: 10.1111/bph.14851] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
93 Roh JW, Chun KH, Kang M, Lee CJ, Oh J, Shim CY, Ahn CM, Kim JS, Kim BK, Park S, Chang HJ, Hong GR, Ko YG, Kang SM, Choi D, Ha JW, Hong MK, Jang Y, Lee SH. PRavastatin Versus FlUVastatin After Statin Intolerance: The PRUV-Intolerance Study With Propensity Score Matching. Am J Med 2019;132:1320-1326.e1. [PMID: 31278931 DOI: 10.1016/j.amjmed.2019.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
94 Lamiquiz-Moneo I, Giné-González J, Alisente S, Bea AM, Pérez-Calahorra S, Marco-Benedí V, Baila-Rueda L, Jarauta E, Cenarro A, Civeira F, Mateo-Gallego R. Effect of bergamot on lipid profile in humans: A systematic review. Crit Rev Food Sci Nutr 2020;60:3133-43. [PMID: 31670973 DOI: 10.1080/10408398.2019.1677554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
95 Horodinschi RN, Stanescu AMA, Bratu OG, Pantea Stoian A, Radavoi DG, Diaconu CC. Treatment with Statins in Elderly Patients. Medicina (Kaunas) 2019;55:E721. [PMID: 31671689 DOI: 10.3390/medicina55110721] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
96 Kajinami K, Tsukamoto K, Koba S, Inoue I, Yamakawa M, Suzuki S, Hamano T, Saito H, Saito Y, Masuda S, Nakayama T, Okamura T, Yamashita S, Kagawa T, Kaneyama J, Kuriyama A, Tanaka R, Hirata A; Statin Intolerance Clinical Guide Working Group; The Japan Society of Hepatology, Japanese Society of Neurology, Japan Atherosclerosis Society, The Japanese Society for the Study of Xenobiotics. Statin Intolerance Clinical Guide 2018. J Atheroscler Thromb 2020;27:375-96. [PMID: 31588101 DOI: 10.5551/jat.50948] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
97 Sivashanmugarajah A, Fulcher J, Sullivan D, Elam M, Jenkins A, Keech A. Suggested clinical approach for the diagnosis and management of ‘statin intolerance’ with an emphasis on muscle‐related side‐effects. Intern Med J 2019;49:1081-91. [DOI: 10.1111/imj.14429] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
98 Robinson JG. New insights into managing symptoms during statin therapy. Progress in Cardiovascular Diseases 2019;62:390-4. [DOI: 10.1016/j.pcad.2019.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
99 Virani SS, Akeroyd JM, Ahmed ST, Krittanawong C, Martin LA, Slagle J, Gobbel GT, Matheny ME, Ballantyne CM, Petersen LA. The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs. J Clin Lipidol 2019;13:797-803.e1. [PMID: 31501043 DOI: 10.1016/j.jacl.2019.08.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
100 Wierzbicki AS, Reynolds TM, Viljoen A. An update on trials of novel lipid-lowering drugs. Curr Opin Cardiol 2018;33:416-22. [PMID: 29561321 DOI: 10.1097/HCO.0000000000000518] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
101 Redelmeier DA, Manzoor F, Thiruchelvam D. Association Between Statin Use and Risk of Dementia After a Concussion. JAMA Neurol. 2019;76:887-896. [PMID: 31107515 DOI: 10.1001/jamaneurol.2019.1148] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
102 Marcum ZA, Huang HC, Romanelli RJ. Statin Dosing Instructions, Medication Adherence, and Low-Density Lipoprotein Cholesterol: a Cohort Study of Incident Statin Users. J Gen Intern Med 2019;34:2559-66. [PMID: 31367867 DOI: 10.1007/s11606-019-05180-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
103 Ahmed EA, Abd-eldayem AM, Aboulhagag NA. The possible protective effects of vitamin D and L-carnitine against used atorvastatin-induced myopathy and hepatotoxicity. Comp Clin Pathol 2019;28:1751-9. [DOI: 10.1007/s00580-019-03016-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
104 Farrah TE, Anand A, Gallacher PJ, Kimmitt R, Carter E, Dear JW, Mills NL, Webb DJ, Dhaun N. Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease. Hypertension 2019;74:323-30. [PMID: 31177906 DOI: 10.1161/HYPERTENSIONAHA.119.12919] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
105 Toth PP, Banach M. Statins: Then and Now. Methodist Debakey Cardiovasc J 2019;15:23-31. [PMID: 31049146 DOI: 10.14797/mdcj-15-1-23] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
106 Wierzbicki AS. Treating lipids in secondary prevention in a developing country: Lies, damn lies and the internet. Int J Clin Pract 2019;73:1-3. [PMID: 31168908 DOI: 10.1111/ijcp.13381] [Reference Citation Analysis]
107 Ward NC, Watts GF, Eckel RH. Response by Ward et al to Letter Regarding Article, "Statin Toxicity: Mechanistic Insights and Clinical Implications". Circ Res 2019;124:e121-2. [PMID: 31170055 DOI: 10.1161/CIRCRESAHA.119.315233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
108 Yandrapalli S, Gupta S, Andries G, Cooper HA, Aronow WS. Drug Therapy of Dyslipidemia in the Elderly. Drugs Aging 2019;36:321-40. [PMID: 30613912 DOI: 10.1007/s40266-018-00632-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
109 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-jones D, Lopez-pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology 2019;73:e285-350. [DOI: 10.1016/j.jacc.2018.11.003] [Cited by in Crossref: 688] [Cited by in F6Publishing: 869] [Article Influence: 229.3] [Reference Citation Analysis]
110 Tuerdi N, Anwaier G, Zhang X, Liu S, Shen W, Liu W, Shen Q, Qi R. Simvastatin nanoliposome induces myocardial and hepatic toxicities due to its absorption enhancement in mice. Asian J Pharm Sci 2020;15:112-20. [PMID: 32175023 DOI: 10.1016/j.ajps.2019.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
111 Ruscica M, Reiner Z, Sirtori CR. Can we further optimize statin therapy to increase tolerability? Expert Opinion on Drug Discovery 2019;14:843-7. [DOI: 10.1080/17460441.2019.1615436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
112 Munkhaugen J, Vethe NT, Fagerland MW, Dammen T, Perk J, Gjertsen E, Otterstad JE, Gullestad L, Bergan S, Husebye E. Statin-associated muscle symptoms in coronary patients: design of a randomized study. Scandinavian Cardiovascular Journal 2019;53:162-8. [DOI: 10.1080/14017431.2019.1612085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
113 Pedro-Botet J, Climent E, Benaiges D. Muscle and statins: from toxicity to the nocebo effect. Expert Opin Drug Saf 2019;18:573-9. [PMID: 31070941 DOI: 10.1080/14740338.2019.1615053] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
114 Ofori-Asenso R, Jakhu A, Zomer E, Curtis AJ, Korhonen MJ, Nelson M, Gambhir M, Tonkin A, Liew D, Zoungas S. Adherence and Persistence Among Statin Users Aged 65 Years and Over: A Systematic Review and Meta-analysis. J Gerontol A Biol Sci Med Sci 2018;73:813-9. [PMID: 28958039 DOI: 10.1093/gerona/glx169] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 13.7] [Reference Citation Analysis]
115 Elseweidy MM, Elswefy SE, Younis NN, Tarek S. Contribution of aorta glycosaminoglycans and PCSK9 to hyperlipidemia in experimental rabbits: the role of 10-dehdrogingerdione as effective modulator. Mol Biol Rep 2019;46:3921-8. [DOI: 10.1007/s11033-019-04836-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
116 Jacobson TA, Cheeley MK, Jones PH, La Forge R, Maki KC, López JAG, Xiang P, Bushnell DM, Martin ML, Cohen JD. The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy. Journal of Clinical Lipidology 2019;13:415-24. [DOI: 10.1016/j.jacl.2019.04.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
117 Lorenzatti AJ, Eliaschewitz FG, Chen Y, Lu J, Baass A, Monsalvo ML, Wang N, Hamer AW, Ge J. Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial. Diabetes Obes Metab 2019;21:1455-63. [PMID: 30821053 DOI: 10.1111/dom.13680] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
118 Takata K, Nicholls SJ. Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. Am J Cardiovasc Drugs 2019;19:113-31. [PMID: 30565156 DOI: 10.1007/s40256-018-0312-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
119 Hadjiphilippou S, Ray KK. Cholesterol-Lowering Agents: Statins—For Everyone? Circ Res 2019;124:354-63. [DOI: 10.1161/circresaha.118.313245] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
120 Nishikido T, Ray KK. Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries. Front Cardiovasc Med 2018;5:199. [PMID: 30761308 DOI: 10.3389/fcvm.2018.00199] [Cited by in Crossref: 13] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
121 Graham I, Shear C, De Graeff P, Boulton C, Catapano AL, Stough WG, Carlsson SC, De Backer G, Emmerich J, Greenfeder S, Kim AM, Lautsch D, Nguyen T, Nissen SE, Prasad K, Ray KK, Robinson JG, Sasiela WJ, Bruins Slot K, Stroes E, Thuren T, Van der Schueren B, Velkovski-Rouyer M, Wasserman SM, Wiklund O, Zouridakis E; European Society of Cardiology Cardiovascular Roundtable. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. Eur Heart J Cardiovasc Pharmacother 2018;4:119-27. [PMID: 29194462 DOI: 10.1093/ehjcvp/pvx031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
122 Doshi P, Sieluk J, Hung A. The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us? J Am Pharm Assoc (2003) 2019;59:195-201. [PMID: 30661956 DOI: 10.1016/j.japh.2018.12.003] [Reference Citation Analysis]
123 Ochs-Balcom HM, Nguyen LM, Ma C, Isackson PJ, Luzum JA, Kitzmiller JP, Tarnopolsky M, Weisman M, Christopher-Stine L, Peltier W, Wortmann RL, Vladutiu GD. Clinical features related to statin-associated muscle symptoms. Muscle Nerve 2019;59:537-43. [PMID: 30549046 DOI: 10.1002/mus.26397] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
124 Mo H, Jeter R, Bachmann A, Yount ST, Shen CL, Yeganehjoo H. The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins. Front Pharmacol. 2019;9:1515. [PMID: 30662405 DOI: 10.3389/fphar.2018.01515] [Cited by in Crossref: 16] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
125 Chien SC, Chen PS, Huang YH, Tang SC, Li YH, Yeh HI. 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance. J Formos Med Assoc 2019;118:1385-92. [PMID: 30584005 DOI: 10.1016/j.jfma.2018.11.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
126 Gupta KK, Ali S, Sanghera RS. Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. Cardiol Ther 2019;8:5-20. [PMID: 30543029 DOI: 10.1007/s40119-018-0123-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
127 Pendergrass SA, Crawford DC. Using Electronic Health Records To Generate Phenotypes For Research. Curr Protoc Hum Genet 2019;100:e80. [PMID: 30516347 DOI: 10.1002/cphg.80] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
128 Colantonio LD, Deng L, Chen L, Farkouh ME, Monda KL, Harrison DJ, Maya JF, Kilgore ML, Muntner P, Rosenson RS. Medical Expenditures Among Medicare Beneficiaries with Statin-Associated Adverse Effects Following Myocardial Infarction. Cardiovasc Drugs Ther 2018;32:601-10. [DOI: 10.1007/s10557-018-6840-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
129 Khoshnejad M, Patel A, Wojtak K, Kudchodkar SB, Humeau L, Lyssenko NN, Rader DJ, Muthumani K, Weiner DB. Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics. Mol Ther 2019;27:188-99. [PMID: 30449662 DOI: 10.1016/j.ymthe.2018.10.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
130 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1046-81. [PMID: 30565953 DOI: 10.1161/CIR.0000000000000624] [Cited by in Crossref: 39] [Cited by in F6Publishing: 104] [Article Influence: 9.8] [Reference Citation Analysis]
131 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082-e1143. [PMID: 30586774 DOI: 10.1161/cir.0000000000000625] [Cited by in Crossref: 250] [Cited by in F6Publishing: 606] [Article Influence: 62.5] [Reference Citation Analysis]
132 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;73:3168-209. [PMID: 30423391 DOI: 10.1016/j.jacc.2018.11.002] [Cited by in Crossref: 433] [Cited by in F6Publishing: 585] [Article Influence: 108.3] [Reference Citation Analysis]
133 Stoekenbroek RM, Kallend D, Wijngaard PL, Kastelein JJ. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program. Future Cardiol 2018;14:433-42. [PMID: 30375244 DOI: 10.2217/fca-2018-0067] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
134 Vassy JL, Brunette CA, Majahalme N, Advani S, MacMullen L, Hau C, Zimolzak AJ, Miller SJ. The Integrating Pharmacogenetics in Clinical Care (I-PICC) Study: Protocol for a point-of-care randomized controlled trial of statin pharmacogenetics in primary care. Contemp Clin Trials 2018;75:40-50. [PMID: 30367991 DOI: 10.1016/j.cct.2018.10.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
135 Vassy JL, Chun S, Advani S, Ludin SA, Smith JG, Alligood EC. Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review. Clin Pharmacol Ther 2019;106:360-73. [PMID: 30137643 DOI: 10.1002/cpt.1223] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
136 Chasioti D, Yao X, Zhang P, Lerner S, Quinney SK, Ning X, Li L, Shen L. Mining Directional Drug Interaction Effects on Myopathy Using the FAERS Database. IEEE J Biomed Health Inform 2019;23:2156-63. [PMID: 30296244 DOI: 10.1109/JBHI.2018.2874533] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
137 Ballantyne CM, Banach M, Mancini GJ, Lepor NE, Hanselman JC, Zhao X, Leiter LA. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis 2018;277:195-203. [DOI: 10.1016/j.atherosclerosis.2018.06.002] [Cited by in Crossref: 117] [Cited by in F6Publishing: 145] [Article Influence: 29.3] [Reference Citation Analysis]
138 Peyser B, Perry EP, Singh K, Gill RD, Mehan MR, Haga SB, Musty MD, Milazzo NA, Savard D, Li Y, Trujilio G, Voora D. Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings. Circ Genom Precis Med 2018;11. [DOI: 10.1161/circgen.118.002228] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
139 Mefford MT, Tajeu GS, Tanner RM, Colantonio LD, Monda KL, Dent R, Farkouh ME, Rosenson RS, Safford MM, Muntner P. Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol 2018;122:768-74. [PMID: 30057227 DOI: 10.1016/j.amjcard.2018.05.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
140 Tuteja S, Rader DJ. SLCO1B1 and Statin Therapy: Getting the GIST of Pharmacogenetic Testing. Circ Genom Precis Med 2018;11. [DOI: 10.1161/circgen.118.002320] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
141 Wang Y, Wang J, Wang S. Comparative Effectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials. Am J Cardiovasc Drugs 2018;18:271-82. [PMID: 29516321 DOI: 10.1007/s40256-018-0270-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
142 Ueda P, Gulayin P, Danaei G. Long-term moderately elevated LDL-cholesterol and blood pressure and risk of coronary heart disease. PLoS One 2018;13:e0200017. [PMID: 30059527 DOI: 10.1371/journal.pone.0200017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
143 Fitzgerald G, Kiernan T. PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives. Expert Review of Cardiovascular Therapy 2018;16:567-78. [DOI: 10.1080/14779072.2018.1497975] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
144 Tanner RM, Safford MM, Monda KL, Taylor B, O'Beirne R, Morris M, Colantonio LD, Dent R, Muntner P, Rosenson RS. Primary Care Physician Perspectives on Barriers to Statin Treatment. Cardiovasc Drugs Ther 2017;31:303-9. [PMID: 28710589 DOI: 10.1007/s10557-017-6738-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
145 Khan S, Holbrook A, Shah BR. Does Googling lead to statin intolerance? International Journal of Cardiology 2018;262:25-7. [DOI: 10.1016/j.ijcard.2018.02.085] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
146 Booth JN 3rd, Colantonio LD, Chen L, Rosenson RS, Monda KL, Safford MM, Kilgore ML, Brown TM, Taylor B, Dent R, Muntner P, Levitan EB. Statin Discontinuation, Reinitiation, and Persistence Patterns Among Medicare Beneficiaries After Myocardial Infarction: A Cohort Study. Circ Cardiovasc Qual Outcomes 2017;10:e003626. [PMID: 29021332 DOI: 10.1161/CIRCOUTCOMES.117.003626] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
147 Wierzbicki AS. The challenges of proprotein convertase subtilisin-kexin-9 inhibitors for lipid guidelines and models of care. Curr Opin Lipidol 2017;28:470-6. [PMID: 28806190 DOI: 10.1097/MOL.0000000000000453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
148 Lansberg P, Lee A, Lee ZV, Subramaniam K, Setia S. Nonadherence to statins: individualized intervention strategies outside the pill box. Vasc Health Risk Manag 2018;14:91-102. [PMID: 29872306 DOI: 10.2147/VHRM.S158641] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
149 Ihle P, Dippel FW, Schubert I. Statin-associated myopathy. Assessment of frequency based on data of all statutory health insurance funds in Germany. Pharmacol Res Perspect 2018;6:e00404. [PMID: 29760929 DOI: 10.1002/prp2.404] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
150 Kim S, Kim H, Kim E, Han S, Rane PP, Fox KM, Zhao Z, Qian Y, Suh HS. Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-based Study in South Korea. Clin Ther 2018;40:940-951.e7. [PMID: 29735297 DOI: 10.1016/j.clinthera.2018.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Booth JN 3rd, Colantonio LD, Rosenson RS, Safford MM, Chen L, Kilgore ML, Brown TM, Taylor B, Dent R, Monda KL, Muntner P, Levitan EB. Healthcare Utilization and Statin Re-Initiation Among Medicare Beneficiaries With a History of Myocardial Infarction. J Am Heart Assoc 2018;7:e008462. [PMID: 29739799 DOI: 10.1161/JAHA.117.008462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
152 Zhang H, Plutzky J, Ge W, Shubina M, Turchin A. Predictors of a successful statin reattempt after an adverse reaction. Journal of Clinical Lipidology 2018;12:643-51. [DOI: 10.1016/j.jacl.2018.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
153 Barry AR, Beach JE, Pearson GJ. Prevention and management of statin adverse effects: A practical approach for pharmacists. Can Pharm J (Ott) 2018;151:179-88. [PMID: 29796131 DOI: 10.1177/1715163518768534] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
154 Ueda P, Lung TW, Lu Y, Salomon JA, Rahimi K, Clarke P, Danaei G. Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England. PLoS One 2018;13:e0190688. [PMID: 29561843 DOI: 10.1371/journal.pone.0190688] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
155 Jacobson TA, Edelman SV, Galipeau N, Shields AL, Mallya UG, Koren A, Davidson MH. Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©. Patient 2017;10:321-34. [PMID: 27981439 DOI: 10.1007/s40271-016-0211-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
156 Wake M, Onishi Y, Guelfucci F, Oh A, Hiroi S, Shimasaki Y, Teramoto T. Treatment patterns in hyperlipidaemia patients based on administrative claim databases in Japan. Atherosclerosis 2018;272:145-52. [PMID: 29604481 DOI: 10.1016/j.atherosclerosis.2018.03.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
157 Hou T, Li Y, Chen W, Heffner RR, Vladutiu GD. Histopathologic and Biochemical Evidence for Mitochondrial Disease Among 279 Patients with Severe Statin Myopathy. J Neuromuscul Dis 2017;4:77-87. [PMID: 28269789 DOI: 10.3233/JND-160184] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
158 Laufs U, Filipiak KJ, Gouni-Berthold I, Catapano AL; SAMS expert working group. Practical aspects in the management of statin-associated muscle symptoms (SAMS). Atheroscler Suppl 2017;26:45-55. [PMID: 28434484 DOI: 10.1016/S1567-5688(17)30024-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
159 Shinozawa E, Amano Y, Yamakawa H, Haba M, Shimada M, Tozawa R. Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents. Pharmacol Res Perspect 2018;6:e00390. [PMID: 29541476 DOI: 10.1002/prp2.390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
160 Hashi S, Sathiyakumar V, Byrne K, Elshazly MB, Jones SR, Martin SS. Statin Safety: What Every Health Care Provider Needs to Know. Curr Cardiovasc Risk Rep 2018;12. [DOI: 10.1007/s12170-018-0565-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
161 Zhu A, Zeng D, Zhang P, Li L. Estimating causal log-odds ratio using the case-control sample and its application in the pharmaco-epidemiology study. Stat Methods Med Res 2019;28:2165-78. [PMID: 29355073 DOI: 10.1177/0962280217750175] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
162 Huang WY, Li CH, Lin CL, Liang JA. Long-term statin use in patients with lung cancer and dyslipidemia reduces the risk of death. Oncotarget 2016;7:42208-15. [PMID: 27283991 DOI: 10.18632/oncotarget.9906] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
163 Alfian SD, Worawutputtapong P, Schuiling-Veninga CCM, van der Schans J, Bos JHJ, Hak E, Denig P. Pharmacy-based predictors of non-persistence with and non-adherence to statin treatment among patients on oral diabetes medication in the Netherlands. Curr Med Res Opin 2018;34:1013-9. [PMID: 29292657 DOI: 10.1080/03007995.2017.1417242] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
164 Jackevicius CA. Elephant in the Room: Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors. Circ Cardiovasc Qual Outcomes 2018;11:e004425. [PMID: 29326147 DOI: 10.1161/CIRCOUTCOMES.117.004425] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
165 Rosenson RS, Gandra SR, McKendrick J, Dent R, Wieffer H, Cheng LI, Catapano AL, Oh P, Kees Hovingh G, Stroes ES. Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries. Cardiovasc Drugs Ther 2017;31:187-95. [PMID: 28466399 DOI: 10.1007/s10557-017-6727-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
166 Zhaori G. RNAi technique, how far is it from pediatrics? Pediatr Investig 2017;1:40-6. [PMID: 32851217 DOI: 10.1002/ped4.12004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
167 Cheng WH, Gaudette É, Goldman DP. PCSK9 Inhibitors Show Value for Patients and the US Health Care System. Value Health 2017;20:1270-8. [PMID: 29241886 DOI: 10.1016/j.jval.2017.05.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
168 Herrett E, Williamson E, Beaumont D, Prowse D, Youssouf N, Brack K, Armitage J, Goldacre B, MacDonald T, Staa TV, Roberts I, Shakur-Still H, Smeeth L. Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care. BMJ Open 2017;7:e016604. [PMID: 29197834 DOI: 10.1136/bmjopen-2017-016604] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
169 Bakar NS, Neely D, Avery P, Brown C, Daly AK, Kamali F. Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study. Clin Pharmacol Ther 2018;104:178-87. [PMID: 28940218 DOI: 10.1002/cpt.887] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
170 Tiniakou E, Christopher-stine L. Immune-mediated necrotizing myopathy associated with statins: history and recent developments. Current Opinion in Rheumatology 2017;29:604-11. [DOI: 10.1097/bor.0000000000000438] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
171 Levy AE, Ho PM. Nonadherence in the Learning Healthcare System: Avoiding a Mountain by Seeing the Bumps. Circ Cardiovasc Qual Outcomes 2017;10:e004283. [PMID: 29021335 DOI: 10.1161/CIRCOUTCOMES.117.004283] [Reference Citation Analysis]
172 Kriegbaum M, Lau SR. Medication non-adherence and uncertainty: Information-seeking and processing in the Danish LIFESTAT survey. Res Social Adm Pharm 2018;14:736-41. [PMID: 29203408 DOI: 10.1016/j.sapharm.2017.09.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
173 Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, Brunham LR, Catapano AL, Elam MB, Mancini GJ, Moriarty PM, Morris PB, Muntner P, Ray KK, Stroes ES, Taylor BA, Taylor VH, Watts GF, Thompson PD. Optimizing Cholesterol Treatment in Patients With Muscle Complaints. Journal of the American College of Cardiology 2017;70:1290-301. [DOI: 10.1016/j.jacc.2017.07.752] [Cited by in Crossref: 121] [Cited by in F6Publishing: 119] [Article Influence: 24.2] [Reference Citation Analysis]
174 Chisnell J, Marshall T, Hyde C, Zhelev Z, Fleming LE. A content analysis of the representation of statins in the British newsprint media. BMJ Open 2017;7:e012613. [PMID: 28827228 DOI: 10.1136/bmjopen-2016-012613] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
175 Lee M, Saver JL, Wu YL, Tang SC, Lee JD, Rao NM, Wang HH, Jeng JS, Lee TH, Chen PC, Ovbiagele B. Utilization of Statins Beyond the Initial Period After Stroke and 1-Year Risk of Recurrent Stroke. J Am Heart Assoc 2017;6:e005658. [PMID: 28768645 DOI: 10.1161/JAHA.117.005658] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
176 Kazi DS, Penko JM, Bibbins-Domingo K. Statins for Primary Prevention of Cardiovascular Disease: Review of Evidence and Recommendations for Clinical Practice. Med Clin North Am 2017;101:689-99. [PMID: 28577620 DOI: 10.1016/j.mcna.2017.03.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
177 Gulizia MM, Colivicchi F, Arca M, Abrignani MG, Perna GP, Mureddu GF, Nardi F, Riccio C; Italian Association of Hospital Cardiologists (ANMCO). ANMCO Position Paper: diagnostic-therapeutic pathway in patients with hypercholesterolaemia and statin intolerance. Eur Heart J Suppl 2017;19:D55-63. [PMID: 28751834 DOI: 10.1093/eurheartj/sux020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
178 Sharma N, Cooper R, Kuh D, Shah I. Associations of statin use with motor performance and myalgia may be modified by 25-hydroxyvitamin D: findings from a British birth cohort. Sci Rep 2017;7:6578. [PMID: 28747665 DOI: 10.1038/s41598-017-06019-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
179 Ramachandran R, Wierzbicki AS. Statins, Muscle Disease and Mitochondria. J Clin Med 2017;6:E75. [PMID: 28757597 DOI: 10.3390/jcm6080075] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
180 Kriegbaum M, Liisberg KB, Wallach-Kildemoes H. Pattern of statin use changes following media coverage of its side effects. Patient Prefer Adherence 2017;11:1151-7. [PMID: 28744105 DOI: 10.2147/PPA.S133168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
181 Serban MC, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, Chen L, Huang L, Dent R, Kent ST, Muntner P, Rosenson RS. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. J Am Coll Cardiol 2017;69:1386-95. [PMID: 28302290 DOI: 10.1016/j.jacc.2016.12.036] [Cited by in Crossref: 160] [Cited by in F6Publishing: 163] [Article Influence: 32.0] [Reference Citation Analysis]
182 du Souich P, Roederer G, Dufour R. Myotoxicity of statins: Mechanism of action. Pharmacology & Therapeutics 2017;175:1-16. [DOI: 10.1016/j.pharmthera.2017.02.029] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 15.0] [Reference Citation Analysis]
183 Pucci G, Cicero AF, Borghi C, Schillaci G. Emerging biologic therapies for hypercholesterolaemia. Expert Opinion on Biological Therapy 2017;17:1077-87. [DOI: 10.1080/14712598.2017.1341485] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
184 Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. J Am Coll Cardiol. 2016;67:2395-2410. [PMID: 27199064 DOI: 10.1016/j.jacc.2016.02.071] [Cited by in Crossref: 267] [Cited by in F6Publishing: 292] [Article Influence: 53.4] [Reference Citation Analysis]
185 AlHajri L, AlHadhrami A, AlMheiri S, AlMutawa Y, AlHashimi Z. The efficacy of evolocumab in the management of hyperlipidemia: a systematic review. Ther Adv Cardiovasc Dis 2017;11:155-69. [PMID: 28488460 DOI: 10.1177/1753944717698925] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
186 Pandya A, Sy S, Cho S, Alam S, Weinstein MC, Gaziano TA. Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves. Med Decis Making 2017;37:802-14. [PMID: 28490271 DOI: 10.1177/0272989X17706081] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
187 Malmasi S, Sandor NL, Hosomura N, Goldberg M, Skentzos S, Turchin A. Canary: An NLP Platform for Clinicians and Researchers. Appl Clin Inform 2017;8:447-53. [PMID: 28466087 DOI: 10.4338/ACI-2017-01-IE-0018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
188 Brennan ET, Joy TR. Management Strategies for Statin-Associated Muscle Symptoms: How Useful Is Same-Statin Rechallenge? Can J Cardiol 2017;33:666-73. [PMID: 28449837 DOI: 10.1016/j.cjca.2017.02.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
189 Pearlman M, Covin Y, Schmidt R, Mortensen EM, Mansi IA. Statins and Lower Gastrointestinal Conditions: A Retrospective Cohort Study. J Clin Pharmacol 2017;57:1053-63. [PMID: 28398604 DOI: 10.1002/jcph.895] [Reference Citation Analysis]
190 Latimer J, Batty JA, Neely RD, Kunadian V. PCSK9 inhibitors in the prevention of cardiovascular disease. J Thromb Thrombolysis 2016;42:405-19. [PMID: 27095708 DOI: 10.1007/s11239-016-1364-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
191 Krähenbühl S, Pavik-Mezzour I, von Eckardstein A. Unmet Needs in LDL-C Lowering: When Statins Won't Do! Drugs 2016;76:1175-90. [PMID: 27456066 DOI: 10.1007/s40265-016-0613-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
192 Qian LJ, Gao Y, Zhang YM, Chu M, Yao J, Xu D. Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials. Sci Rep 2017;7:238. [PMID: 28331223 DOI: 10.1038/s41598-017-00316-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
193 Wierzbicki AS, Grant P. Drugs for hypercholesterolaemia - from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition. Clin Med (Lond) 2016;16:353-7. [PMID: 27481380 DOI: 10.7861/clinmedicine.16-4-353] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
194 Khedri M, Szummer K, Carrero J, Jernberg T, Evans M, Jacobson SH, Spaak J. Systematic underutilisation of secondary preventive drugs in patients with acute coronary syndrome and reduced renal function. Eur J Prev Cardiolog 2017;24:724-34. [DOI: 10.1177/2047487317693950] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
195 Jaworski K, Jankowski P, Kosior DA. PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade. Arch Med Sci 2017;13:914-29. [PMID: 28721159 DOI: 10.5114/aoms.2017.65239] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
196 Backes JM, Ruisinger JF, Gibson CA, Moriarty PM. Statin-associated muscle symptoms—Managing the highly intolerant. Journal of Clinical Lipidology 2017;11:24-33. [DOI: 10.1016/j.jacl.2017.01.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
197 Laufs U, Scharnagl H, Halle M, Windler E, Endres M, März W. Treatment Options for Statin-Associated Muscle Symptoms. Dtsch Arztebl Int 2015;112:748-55. [PMID: 26575138 DOI: 10.3238/arztebl.2015.0748] [Cited by in Crossref: 13] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
198 Sposito AC, Faria Neto JR, Carvalho LSFD, Lorenzatti A, Cafferata A, Elikir G, Esteban E, Morales Villegas EC, Bodanese LC, Alonso R, Ruiz AJ, Rocha VZ, Faludi AA, Xavier HT, Coelho OR, Assad MH, Izar MC, Santos RD, Fonseca FA, Mello e Silva A, Silva PMD, Bertolami MC. Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. Current Medical Research and Opinion 2017;33:239-51. [DOI: 10.1080/03007995.2016.1252740] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
199 van der Ploeg MA, Poortvliet RK, van Blijswijk SC, den Elzen WP, van Peet PG, de Ruijter W, Blom JW, Gussekloo J. Statin Use and Self-Reported Hindering Muscle Complaints in Older Persons: A Population Based Study. PLoS One 2016;11:e0166857. [PMID: 27911918 DOI: 10.1371/journal.pone.0166857] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
200 Rodriguez F, Lin S, Maron DJ, Knowles JW, Virani SS, Heidenreich PA. Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines. Am Heart J 2016;182:97-102. [PMID: 27914506 DOI: 10.1016/j.ahj.2016.09.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
201 Al-Mohaissen MA, Ignaszewski MJ, Frohlich J, Ignaszewski AP. Statin-Associated Muscle Adverse Events: Update for clinicians. Sultan Qaboos Univ Med J 2016;16:e406-15. [PMID: 28003885 DOI: 10.18295/squmj.2016.16.04.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
202 Flueckiger P, Qureshi W, Michos ED, Blaha M, Burke G, Sandfort V, Herrington D, Yeboah J. Guideline-based statin/lipid-lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: The Multi-Ethnic Study of Atherosclerosis (MESA). Clin Cardiol 2017;40:163-9. [PMID: 27859433 DOI: 10.1002/clc.22642] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
203 Rizos CV, Elisaf MS. Statin myopathy: navigating the maze. Curr Med Res Opin 2017;33:327-9. [PMID: 27805428 DOI: 10.1080/03007995.2016.1255601] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
204 Chi CL, Wang J, Clancy TR, Robinson JG, Tonellato PJ, Adam TJ. Big Data Cohort Extraction to Facilitate Machine Learning to Improve Statin Treatment. West J Nurs Res 2017;39:42-62. [PMID: 30208771 DOI: 10.1177/0193945916673059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
205 Blom DJ, Koren MJ, Roth E, Monsalvo ML, Djedjos CS, Nelson P, Elliott M, Wasserman SM, Ballantyne CM, Holman RR. Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes Obes Metab. 2017;19:98-107. [PMID: 27619750 DOI: 10.1111/dom.12788] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
206 Graham JH, Sanchez RJ, Saseen JJ, Mallya UG, Panaccio MP, Evans MA. Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system. J Clin Lipidol 2017;11:70-79.e1. [PMID: 28391913 DOI: 10.1016/j.jacl.2016.10.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
207 Millán J, Pedro-Botet J, Climent E, Millán J, Rius J. [Statin associated myopathy in clinical practice. Results of DAMA study]. Clin Investig Arterioscler 2017;29:7-12. [PMID: 27717598 DOI: 10.1016/j.arteri.2016.07.003] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
208 Algharably EA, Filler I, Rosenfeld S, Grabowski K, Kreutz R. Statin intolerance - a question of definition. Expert Opin Drug Saf 2017;16:55-63. [PMID: 27645111 DOI: 10.1080/14740338.2017.1238898] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
209 Swallow DM, Lawton MA, Grosset KA, Malek N, Klein J, Baig F, Ruffmann C, Bajaj NP, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Morris HR, Williams N, Wood NW, Hu MT, Grosset DG. Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. J Neurol Neurosurg Psychiatry 2016;87:1183-90. [PMID: 27671901 DOI: 10.1136/jnnp-2016-313642] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
210 Zhang H, Plutzky J, Shubina M, Turchin A. Risk factors for lack of statin therapy in patients with diabetes and coronary artery disease. J Clin Lipidol 2016;10:1406-13. [PMID: 27919358 DOI: 10.1016/j.jacl.2016.09.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
211 Miedema MD, Virani SS. Harder-to-Treat Patients: Recognizing Them and Adapting Treatment Strategies. Am J Cardiol 2016;118:13A-8A. [PMID: 27620355 DOI: 10.1016/j.amjcard.2016.05.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
212 Toth PP. Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. Am J Cardiol 2016;118:19A-32A. [PMID: 27620356 DOI: 10.1016/j.amjcard.2016.05.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
213 Stroes E, Guyton JR, Lepor N, Civeira F, Gaudet D, Watts GF, Baccara-Dinet MT, Lecorps G, Manvelian G, Farnier M; ODYSSEY CHOICE II Investigators. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. J Am Heart Assoc 2016;5:e003421. [PMID: 27625344 DOI: 10.1161/JAHA.116.003421] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 8.3] [Reference Citation Analysis]
214 Muntean DM, Thompson PD, Catapano AL, Stasiolek M, Fabis J, Muntner P, Serban MC, Banach M. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms? Drug Discov Today 2017;22:85-96. [PMID: 27634340 DOI: 10.1016/j.drudis.2016.09.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
215 Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532-2561. [PMID: 27616593 DOI: 10.1016/s0140-6736(16)31357-5] [Cited by in Crossref: 853] [Cited by in F6Publishing: 877] [Article Influence: 142.2] [Reference Citation Analysis]
216 Colletti A, Derosa G, Cicero AF. Retargeting the management of hypercholesterolemia - focus on evolocumab. Ther Clin Risk Manag 2016;12:1365-76. [PMID: 27660454 DOI: 10.2147/TCRM.S116679] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
217 Saxon DR, Eckel RH. Statin Intolerance: A Literature Review and Management Strategies. Progress in Cardiovascular Diseases 2016;59:153-64. [DOI: 10.1016/j.pcad.2016.07.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
218 Yusuf S. Why do people not take life-saving medications? The case of statins. The Lancet 2016;388:943-5. [DOI: 10.1016/s0140-6736(16)31532-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
219 Khine H, Yuet WC, Adams-Huet B, Ahmad Z. Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia. Am Heart J 2016;179:1-9. [PMID: 27595674 DOI: 10.1016/j.ahj.2016.05.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
220 Joy TR, Brennan ET. Management strategies in patients with statin-associated muscle symptoms: What is the best strategy? Journal of Clinical Lipidology 2016;10:1067-72. [DOI: 10.1016/j.jacl.2016.06.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
221 Schulman KL, Lamerato LE, Dalal MR, Sung J, Jhaveri M, Koren A, Mallya UG, Foody JM. Development and Validation of Algorithms to Identify Statin Intolerance in a US Administrative Database. Value in Health 2016;19:852-60. [DOI: 10.1016/j.jval.2016.03.1858] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
222 Agabiti Rosei E, Salvetti M. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. High Blood Press Cardiovasc Prev 2016;23:217-30. [PMID: 27567901 DOI: 10.1007/s40292-016-0155-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
223 Nilsson G, Samuelsson E, Söderström L, Mooe T. Low use of statins for secondary prevention in primary care: a survey in a northern Swedish population. BMC Fam Pract 2016;17:110. [PMID: 27515746 DOI: 10.1186/s12875-016-0505-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
224 Goel H, Dunbar RL. Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics. Curr Atheroscler Rep 2016;18:17. [PMID: 26932224 DOI: 10.1007/s11883-016-0570-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
225 Gencer B, Nanchen D. Identifying familial hypercholesterolemia in acute coronary syndrome: . Current Opinion in Lipidology 2016;27:375-81. [DOI: 10.1097/mol.0000000000000311] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
226 Qu H, Guo M, Kou N, Wu HT, Zhang Y, Gao ZY, Shi DZ. Simvastatin monotherapy as a potential option for statin-associated muscle symptoms: a case report. J Clin Pharm Ther 2016;41:568-71. [PMID: 27425755 DOI: 10.1111/jcpt.12419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
227 Dunbar RL, Goel H. Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens. Curr Atheroscler Rep 2016;18:11. [PMID: 26876225 DOI: 10.1007/s11883-016-0563-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
228 Sabatine MS, Underberg JA, Koren M, Baum SJ. Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice. Postgrad Med 2016;128 Suppl 1:31-9. [PMID: 27422124 DOI: 10.1080/00325481.2016.1208895] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
229 Rash JA, Campbell DJ, Tonelli M, Campbell TS. A systematic review of interventions to improve adherence to statin medication: What do we know about what works? Prev Med 2016;90:155-69. [PMID: 27413005 DOI: 10.1016/j.ypmed.2016.07.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
230 Colantonio LD, Kent ST, Huang L, Chen L, Monda KL, Serban M, Manthripragada A, Kilgore ML, Rosenson RS, Muntner P. Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data. Cardiovasc Drugs Ther 2016;30:525-33. [DOI: 10.1007/s10557-016-6680-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
231 Mancini GJ, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pearson GJ, Pope J, Tashakkor AY. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Canadian Journal of Cardiology 2016;32:S35-65. [DOI: 10.1016/j.cjca.2016.01.003] [Cited by in Crossref: 125] [Cited by in F6Publishing: 137] [Article Influence: 20.8] [Reference Citation Analysis]
232 Lakey WC, Greyshock NG, Kelley CE, Siddiqui MA, Ahmad U, Lokhnygina YV, Guyton JR. Statin intolerance in a referral lipid clinic. Journal of Clinical Lipidology 2016;10:870-879.e3. [DOI: 10.1016/j.jacl.2016.03.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
233 Maghsoodi N, Wierzbicki AS. Statin myopathy: over-rated and under-treated? Current Opinion in Cardiology 2016;31:417-25. [DOI: 10.1097/hco.0000000000000282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
234 Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. Journal of Clinical Lipidology 2016;10:739-47. [DOI: 10.1016/j.jacl.2016.05.002] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 10.8] [Reference Citation Analysis]
235 Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox J. Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database. BMJ 2016;353:i3305. [PMID: 27353261 DOI: 10.1136/bmj.i3305] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 10.0] [Reference Citation Analysis]
236 Matthews A, Herrett E, Gasparrini A, Van Staa T, Goldacre B, Smeeth L, Bhaskaran K. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. BMJ 2016;353:i3283. [PMID: 27353418 DOI: 10.1136/bmj.i3283] [Cited by in Crossref: 112] [Cited by in F6Publishing: 112] [Article Influence: 18.7] [Reference Citation Analysis]
237 Ito MK, Santos RD. PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia. J Clin Pharmacol 2017;57:7-32. [PMID: 27195910 DOI: 10.1002/jcph.766] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
238 Patel J, Martin SS, Banach M. Expert opinion: the therapeutic challenges faced by statin intolerance. Expert Opinion on Pharmacotherapy 2016;17:1497-507. [DOI: 10.1080/14656566.2016.1197202] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
239 Rash JA, Lavoie KL, Sigal RJ, Campbell DJ, Manns BJ, Tonelli M, Campbell TS. The OPTIMIZE trial: Rationale and design of a randomized controlled trial of motivational enhancement therapy to improve adherence to statin medication. Contemp Clin Trials. 2016;49:47-56. [PMID: 27282119 DOI: 10.1016/j.cct.2016.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
240 O'Keeffe AG, Nazareth I, Petersen I. Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care data. Clin Epidemiol 2016;8:123-32. [PMID: 27313477 DOI: 10.2147/CLEP.S104258] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
241 Christiansen MK, Jensen JM, Brøndberg AK, Bøtker HE, Jensen HK. Cardiovascular risk factor control is insufficient in young patients with coronary artery disease. Vasc Health Risk Manag 2016;12:219-27. [PMID: 27307744 DOI: 10.2147/VHRM.S106436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
242 Brinton EA, Maki KC, Jacobson TA, Sponseller CA, Cohen JD. Metabolic syndrome is associated with muscle symptoms among statin users. J Clin Lipidol 2016;10:1022-9. [PMID: 27578135 DOI: 10.1016/j.jacl.2016.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
243 Stulc T, Ceška R, Gotto AM Jr. Statin Intolerance: the Clinician's Perspective. Curr Atheroscler Rep 2015;17:69. [PMID: 26490078 DOI: 10.1007/s11883-015-0552-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
244 Halava H, Huupponen R, Pentti J, Kivimäki M, Vahtera J. Predictors of first-year statin medication discontinuation: A cohort study. J Clin Lipidol 2016;10:987-95. [PMID: 27578131 DOI: 10.1016/j.jacl.2016.04.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
245 Zhang H, Plutzky J, Shubina M, Turchin A. Drivers of the Sex Disparity in Statin Therapy in Patients with Coronary Artery Disease: A Cohort Study. PLoS One 2016;11:e0155228. [PMID: 27148965 DOI: 10.1371/journal.pone.0155228] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
246 Fernandes V, Santos MJ, Pérez A. Statin-related myotoxicity. Endocrinología y Nutrición 2016;63:239-49. [DOI: 10.1016/j.endonu.2016.01.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
247 Jakobsson S, Huber D, Björklund F, Mooe T. Implementation of a new guideline in cardiovascular secondary preventive care: subanalysis of a randomized controlled trial. BMC Cardiovasc Disord 2016;16:77. [PMID: 27129980 DOI: 10.1186/s12872-016-0252-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
248 de Vries FM, Voorham J, Hak E, Denig P. Prescribing patterns, adherence and LDL-cholesterol response of type 2 diabetes patients initiating statin on low-dose versus standard-dose treatment: a descriptive study. Int J Clin Pract 2016;70:482-92. [PMID: 27125890 DOI: 10.1111/ijcp.12806] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
249 Laufs U, Karmann B, Pittrow D. Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clin Res Cardiol 2016;105:783-90. [PMID: 27120330 DOI: 10.1007/s00392-016-0991-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
250 Jetty V, Glueck CJ, Wang P, Shah P, Prince M, Lee K, Goldenberg M, Kumar A. Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance. N Am J Med Sci 2016;8:156-62. [PMID: 27114973 DOI: 10.4103/1947-2714.179133] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
251 Kones R, Rumana U. Current Treatment of Dyslipidemia: A New Paradigm for Statin Drug Use and the Need for Additional Therapies. Drugs 2015;75:1187-99. [PMID: 26115727 DOI: 10.1007/s40265-015-0428-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
252 Waters DD, Hsue PY, Bangalore S. PCSK9 Inhibitors for Statin Intolerance? JAMA 2016;315:1571-2. [PMID: 27039138 DOI: 10.1001/jama.2016.3670] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
253 Ascaso JF. Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia. Endocrinol Nutr 2016;63:255-7. [PMID: 27050861 DOI: 10.1016/j.endonu.2016.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
254 Barrett B, Ricco J, Wallace M, Kiefer D, Rakel D. Communicating statin evidence to support shared decision-making. BMC Fam Pract 2016;17:41. [PMID: 27048421 DOI: 10.1186/s12875-016-0436-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
255 Karalis DG, Wild RA, Maki KC, Gaskins R, Jacobson TA, Sponseller CA, Cohen JD. Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study. J Clin Lipidol 2016;10:833-41. [PMID: 27578114 DOI: 10.1016/j.jacl.2016.02.016] [Cited by in Crossref: 42] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]
256 Miller PE, Martin SS. Approach to Statin Use in 2016: an Update. Curr Atheroscler Rep 2016;18. [DOI: 10.1007/s11883-016-0578-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
257 Dixon DL, Donohoe KL, Ogbonna KC, Barden SM. Current drug treatment of hyperlipidemia in older adults. Drugs Aging. 2015;32:127-138. [PMID: 25637391 DOI: 10.1007/s40266-015-0240-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
258 Nissen SE, Dent-Acosta RE, Rosenson RS, Stroes E, Sattar N, Preiss D, Mancini GB, Ballantyne CM, Catapano A, Gouni-Berthold I, Stein EA, Xue A, Wasserman SM, Scott R, Thompson PD; GAUSS-3 Investigators. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. Clin Cardiol 2016;39:137-44. [PMID: 26946077 DOI: 10.1002/clc.22518] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
259 Banach M, Serban MC. Discussion around statin discontinuation in older adults and patients with wasting diseases. J Cachexia Sarcopenia Muscle 2016;7:396-9. [PMID: 27030814 DOI: 10.1002/jcsm.12109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
260 Hendrani AD, Adesiyun T, Quispe R, Jones SR, Stone NJ, Blumenthal RS, Martin SS. Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. World J Cardiol 2016; 8(2): 201-210 [PMID: 26981215 DOI: 10.4330/wjc.v8.i2.201] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
261 Quek RGW, Fox KM, Wang L, Li L, Gandra SR, Wong ND. A US Claims-Based Analysis of Real-World Lipid-Lowering Treatment Patterns in Patients With High Cardiovascular Disease Risk or a Previous Coronary Event. Am J Cardiol 2016;117:495-500. [PMID: 26742468 DOI: 10.1016/j.amjcard.2015.11.035] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
262 Perestelo-pérez L, Rivero-santana A, Boronat M, Sánchez-afonso JA, Pérez-ramos J, Montori VM, Serrano-aguilar P. Effect of the statin choice encounter decision aid in Spanish patients with type 2 diabetes: A randomized trial. Patient Education and Counseling 2016;99:295-9. [DOI: 10.1016/j.pec.2015.08.032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
263 Spence JD, Dresser GK. Overcoming Challenges With Statin Therapy. J Am Heart Assoc 2016;5:e002497. [PMID: 26819251 DOI: 10.1161/JAHA.115.002497] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
264 Pirillo A, Catapano AL. Statin intolerance: diagnosis and remedies. Curr Cardiol Rep 2015;17:27. [PMID: 25894795 DOI: 10.1007/s11886-015-0582-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
265 Newman CB, Tobert JA. Comment on the article by Moriarty et al. Journal of Clinical Lipidology 2016;10:209-10. [DOI: 10.1016/j.jacl.2015.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
266 Banach M, Aronow WS, Serban MC, Rysz J, Voroneanu L, Covic A. Lipids, blood pressure and kidney update 2015. Lipids Health Dis 2015;14:167. [PMID: 26718096 DOI: 10.1186/s12944-015-0169-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
267 Hovingh GK, Gandra SR, McKendrick J, Dent R, Wieffer H, Catapano AL, Oh P, Rosenson RS, Stroes ES. Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey. Atherosclerosis 2016;245:111-7. [PMID: 26717273 DOI: 10.1016/j.atherosclerosis.2015.12.015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 6.1] [Reference Citation Analysis]
268 Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J 2016;37:908-16. [PMID: 26643266 DOI: 10.1093/eurheartj/ehv641] [Cited by in Crossref: 164] [Cited by in F6Publishing: 147] [Article Influence: 23.4] [Reference Citation Analysis]
269 Laufs U, Scharnagl H, März W. Statin intolerance: . Current Opinion in Lipidology 2015;26:492-501. [DOI: 10.1097/mol.0000000000000236] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
270 Wadhera RK, Steen DL, Khan I, Giugliano RP, Foody JM. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol 2016;10:472-89. [PMID: 27206934 DOI: 10.1016/j.jacl.2015.11.010] [Cited by in Crossref: 121] [Cited by in F6Publishing: 134] [Article Influence: 17.3] [Reference Citation Analysis]
271 Shantha G, Robinson J. Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids. Clin Pharmacol Ther 2016;99:59-71. [DOI: 10.1002/cpt.281] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
272 Djulbegovic B, Tsalatsanis A, Hozo I. Determining optimal threshold for statins prescribing: individualization of statins treatment for primary prevention of cardiovascular disease. J Eval Clin Pract 2017;23:241-50. [PMID: 26555150 DOI: 10.1111/jep.12473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
273 Harrison TN, Green KR, Liu IL, Vansomphone SS, Handler J, Scott RD, Cheetham TC, Reynolds K. Automated Outreach for Cardiovascular-Related Medication Refill Reminders. J Clin Hypertens (Greenwich) 2016;18:641-6. [PMID: 26542896 DOI: 10.1111/jch.12723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
274 Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, Mckenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. Journal of Clinical Lipidology 2015;9:S1-S122.e1. [DOI: 10.1016/j.jacl.2015.09.002] [Cited by in Crossref: 243] [Cited by in F6Publishing: 252] [Article Influence: 34.7] [Reference Citation Analysis]
275 Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox J. Patients who discontinued statin treatment: a protocol for cohort study using primary care data. BMJ Open 2015;5:e008701. [PMID: 26493458 DOI: 10.1136/bmjopen-2015-008701] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
276 Yang E. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough? Clin Pharmacol Ther 2015;98:590-601. [DOI: 10.1002/cpt.263] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
277 Unni SK, Quek RG, Biskupiak J, Lee VC, Ye X, Gandra SR. Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States. J Clin Lipidol 2016;10:63-71.e1-3. [PMID: 26892122 DOI: 10.1016/j.jacl.2015.09.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
278 Quek RG, Fox KM, Wang L, Li L, Gandra SR, Wong ND. Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk. BMJ Open Diabetes Res Care 2015;3:e000132. [PMID: 26435839 DOI: 10.1136/bmjdrc-2015-000132] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
279 Stock J. Statin-associated muscle symptoms EAS Consensus Panel paper focuses on this neglected patient group. Atherosclerosis 2015;242:346-50. [DOI: 10.1016/j.atherosclerosis.2015.06.049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
280 Verbeek R, Stoekenbroek RM, Hovingh GK. PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia. European Journal of Pharmacology 2015;763:38-47. [DOI: 10.1016/j.ejphar.2015.03.099] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
281 Preiss D, Sattar N. Classification of reported statin intolerance. Curr Opin Lipidol 2015;26:65-6. [PMID: 25551804 DOI: 10.1097/MOL.0000000000000149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
282 Tobert JA, Newman CB. Statin tolerability: In defence of placebo-controlled trials. Eur J Prev Cardiol 2016;23:891-6. [PMID: 26318980 DOI: 10.1177/2047487315602861] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
283 Birtcher K. When compliance is an issue-how to enhance statin adherence and address adverse effects. Curr Atheroscler Rep 2015;17:471. [PMID: 25410047 DOI: 10.1007/s11883-014-0471-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
284 DuBroff R, de Lorgeril M. Cholesterol confusion and statin controversy. World J Cardiol 2015; 7(7): 404-409 [PMID: 26225201 DOI: 10.4330/wjc.v7.i7.404] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
285 Cornier MA, Eckel RH. Non-traditional dosing of statins in statin-intolerant patients-is it worth a try? Curr Atheroscler Rep 2015;17:475. [PMID: 25432858 DOI: 10.1007/s11883-014-0475-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
286 Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA 2015;314:142-50. [PMID: 26172894 DOI: 10.1001/jama.2015.6822] [Cited by in Crossref: 154] [Cited by in F6Publishing: 135] [Article Influence: 22.0] [Reference Citation Analysis]
287 Joseph L, Robinson JG. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Progress in Cardiovascular Diseases 2015;58:19-31. [DOI: 10.1016/j.pcad.2015.04.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
288 Simons JE, Holbrook AM, Don-wauchope AC. Successful reintroduction of statin therapy after statin-associated rhabdomyolysis. Journal of Clinical Lipidology 2015;9:594-6. [DOI: 10.1016/j.jacl.2015.03.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
289 Hirsh BJ, Smilowitz NR, Rosenson RS, Fuster V, Sperling LS. Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome. Journal of the American College of Cardiology 2015;66:184-92. [DOI: 10.1016/j.jacc.2015.05.030] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 9.0] [Reference Citation Analysis]
290 Cicero AF, Colletti A, Borghi C. Profile of evolocumab and its potential in the treatment of hyperlipidemia. Drug Des Devel Ther. 2015;9:3073-3082. [PMID: 26109850 DOI: 10.2147/dddt.s67498] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
291 Martin SS, Sperling LS, Blaha MJ, Wilson PW, Gluckman TJ, Blumenthal RS, Stone NJ. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol. 2015;65:1361-1368. [PMID: 25835448 DOI: 10.1016/j.jacc.2015.01.043] [Cited by in Crossref: 102] [Cited by in F6Publishing: 100] [Article Influence: 14.6] [Reference Citation Analysis]
292 Taylor BA, Thompson PD. Muscle-related side-effects of statins: from mechanisms to evidence-based solutions. Current Opinion in Lipidology 2015;26:221-7. [DOI: 10.1097/mol.0000000000000174] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.9] [Reference Citation Analysis]
293 Fitchett DH, Hegele RA, Verma S. Cardiology patient page. Statin intolerance. Circulation 2015;131:e389-91. [PMID: 25825402 DOI: 10.1161/CIRCULATIONAHA.114.013189] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
294 Brooks JM, Cook E, Chapman CG, Schroeder MC, A Chrischilles E, Schneider KM, Kulchaitanaroaj P, Robinson J. Statin use after acute myocardial infarction by patient complexity: are the rates right? Med Care 2015;53:324-31. [PMID: 25719431 DOI: 10.1097/MLR.0000000000000322] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
295 van Staa TP, Carr DF, O'Meara H, McCann G, Pirmohamed M. Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment. Br J Clin Pharmacol 2014;78:649-59. [PMID: 24602118 DOI: 10.1111/bcp.12367] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
296 Pastore RL, Brooks JT, Carbone JW. Paleolithic nutrition improves plasma lipid concentrations of hypercholesterolemic adults to a greater extent than traditional heart-healthy dietary recommendations. Nutr Res 2015;35:474-9. [PMID: 26003334 DOI: 10.1016/j.nutres.2015.05.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
297 Qureshi N, Minhas R, Wierzbicki AS. Prioritizing health outcomes in a limited world: writing lipid guidelines. Curr Opin Lipidol 2015;26:188-94. [PMID: 25887682 DOI: 10.1097/MOL.0000000000000170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
298 Page MM, Watts GF. Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention. Expert Opinion on Emerging Drugs 2015;20:299-312. [DOI: 10.1517/14728214.2015.1035709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
299 Khayznikov M, Hemachrandra K, Pandit R, Kumar A, Wang P, Glueck CJ. Statin Intolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in Most Cases be Safely Resolved by Vitamin D Supplementation. N Am J Med Sci 2015;7:86-93. [PMID: 25838999 DOI: 10.4103/1947-2714.153919] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 9.3] [Reference Citation Analysis]
300 Schoen MW, Salas J, Scherrer JF, Buckhold FR. Cholesterol treatment and changes in guidelines in an academic medical practice. Am J Med 2015;128:403-9. [PMID: 25460526 DOI: 10.1016/j.amjmed.2014.10.039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
301 Turin A, Pandit J, Stone NJ. Statins and Nonadherence: Should We RELATE Better? J Cardiovasc Pharmacol Ther 2015;20:447-56. [DOI: 10.1177/1074248415578170] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
302 Patel J, Superko HR, Martin SS, Blumenthal RS, Christopher-Stine L. Genetic and immunologic susceptibility to statin-related myopathy. Atherosclerosis 2015;240:260-71. [PMID: 25818852 DOI: 10.1016/j.atherosclerosis.2015.03.025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
303 Mckenney JM. Understanding PCSK9 and anti-PCSK9 therapies. Journal of Clinical Lipidology 2015;9:170-86. [DOI: 10.1016/j.jacl.2015.01.001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 5.9] [Reference Citation Analysis]
304 Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:1012-22. [PMID: 25694464 DOI: 10.1093/eurheartj/ehv043] [Cited by in Crossref: 675] [Cited by in F6Publishing: 680] [Article Influence: 96.4] [Reference Citation Analysis]
305 Ye Y, Xu H, Quan L, Zhu L, Zeng J, Zhou T, Zou C, Cheng Q, Bu S, Tan W. The Lipid-lowering Effects of R-bambuterol in Healthy Chinese Volunteers: A Randomized Phase I Clinical Study. EBioMedicine 2015;2:356-64. [PMID: 26137575 DOI: 10.1016/j.ebiom.2015.02.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
306 Johansen ME, Green LA, Sen A, Kircher S, Richardson CR. Cardiovascular risk and statin use in the United States. Ann Fam Med 2014;12:215-23. [PMID: 24821892 DOI: 10.1370/afm.1641] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
307 Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA;  The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8:S58-S71. [PMID: 24793443 DOI: 10.1016/j.jacl.2014.03.004] [Cited by in Crossref: 262] [Cited by in F6Publishing: 249] [Article Influence: 32.8] [Reference Citation Analysis]
308 Gokani VJ, Sidloff D, Bath MF, Bown MJ, Sayers RD, Choke E. A retrospective study: Factors associated with the risk of abdominal aortic aneurysm rupture. Vascul Pharmacol 2015;65-66:13-6. [PMID: 25485708 DOI: 10.1016/j.vph.2014.11.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
309 Fadini GP, Rigato M, Boscari F, Cappellari R, Menegazzo L, Pilutti C, Iori E, Marescotti M, Plebani M, Albiero M, Avogaro A. Short-term statin discontinuation increases endothelial progenitor cells without inflammatory rebound in type 2 diabetic patients. Vascul Pharmacol 2015;67-69:21-9. [PMID: 25483979 DOI: 10.1016/j.vph.2014.11.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
310 Gouni-Berthold I, Berthold HK. PCSK9 antibodies for the treatment of hypercholesterolemia. Nutrients 2014;6:5517-33. [PMID: 25470376 DOI: 10.3390/nu6125517] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
311 Munisso M, Obika S, Yamaoka T. Nucleic acid delivery systems based on poly(galactosyl ureaethyl methacrylate-b-dimethylamino ethyl methacrylate) diblock copolymers. Carbohydrate Polymers 2014;114:288-96. [DOI: 10.1016/j.carbpol.2014.08.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
312 Farag MM, Mohamed MB, Youssef EA. Assessment of hepatic function, oxidant/antioxidant status, and histopathological changes in rats treated with atorvastatin: Effect of dose and acute intoxication with acetaminophen. Hum Exp Toxicol 2015;34:828-37. [PMID: 25425547 DOI: 10.1177/0960327114559991] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
313 Morrison FJ, Zhang H, Skentzos S, Shubina M, Bentley-Lewis R, Turchin A. Reasons for discontinuation of lipid-lowering medications in patients with chronic kidney disease. Cardiorenal Med 2014;4:225-33. [PMID: 25737687 DOI: 10.1159/000368914] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
314 Riedel DJ, Jourdain G. Potential impact of statins on cancer incidence in HIV-infected patients. AIDS 2014;28:2475-6. [PMID: 25265231 DOI: 10.1097/QAD.0000000000000402] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
315 Bifulco M. Debate on adverse effects of statins. European Journal of Internal Medicine 2014;25:e95. [DOI: 10.1016/j.ejim.2014.08.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
316 Auer J, Sinzinger H, Franklin B, Berent R. Muscle- and skeletal-related side-effects of statins: tip of the iceberg? Eur J Prev Cardiolog 2015;23:88-110. [DOI: 10.1177/2047487314550804] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
317 Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ 2014;349:g3743. [PMID: 25035309 DOI: 10.1136/bmj.g3743] [Cited by in Crossref: 115] [Cited by in F6Publishing: 111] [Article Influence: 14.4] [Reference Citation Analysis]
318 Keen HI, Krishnarajah J, Bates TR, Watts GF. Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century? Expert Opinion on Drug Safety 2014;13:1227-39. [DOI: 10.1517/14740338.2014.937422] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
319 Soverow J, Watson K. Is there sufficient enhancement of the reduction in CVD rates after a decade of statin therapy to justify continuation? Curr Atheroscler Rep 2014;16:432. [PMID: 24899387 DOI: 10.1007/s11883-014-0432-2] [Reference Citation Analysis]
320 Ahmad Z. Statin intolerance. Am J Cardiol 2014;113:1765-71. [PMID: 24792743 DOI: 10.1016/j.amjcard.2014.02.033] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 9.3] [Reference Citation Analysis]
321 Breslow JL. Perspective on the 2013 American Heart Association/American College of Cardiology guideline for the use of statins in primary prevention of low-risk individuals. Circ Res 2014;114:758-60. [PMID: 24577963 DOI: 10.1161/CIRCRESAHA.114.303333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
322 Tompkins R, Schwartzbard A, Gianos E, Fisher E, Weintraub H. A Current Approach to Statin Intolerance. Clin Pharmacol Ther 2014;96:74-80. [DOI: 10.1038/clpt.2014.84] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
323 Upmeier E, Korhonen MJ, Rikala M, Helin-salmivaara A, Huupponen R. Older Statin Initiators in Finland—Cardiovascular Risk Profiles and Persistence of Use. Cardiovasc Drugs Ther 2014;28:263-72. [DOI: 10.1007/s10557-014-6517-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
324 Mogadam M. Do statins increase the risk of diabetes or is it guilt by association?: . Current Opinion in Endocrinology & Diabetes and Obesity 2014;21:140-5. [DOI: 10.1097/med.0000000000000050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
325 Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541-2548. [PMID: 24694531 DOI: 10.1016/j.jacc.2014.03.019] [Cited by in Crossref: 351] [Cited by in F6Publishing: 341] [Article Influence: 43.9] [Reference Citation Analysis]
326 Li JH, Joy SV, Haga SB, Orlando LA, Kraus WE, Ginsburg GS, Voora D. Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients. J Pers Med 2014;4:147-62. [PMID: 25563221 DOI: 10.3390/jpm4020147] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
327 Palamaner Subash Shantha G, Ramos J, Thomas-Hemak L, Pancholy SB. Association of vitamin D and incident statin induced myalgia--a retrospective cohort study. PLoS One 2014;9:e88877. [PMID: 24586424 DOI: 10.1371/journal.pone.0088877] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
328 Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, Xue A, Scott R, Wasserman SM, Stroes E. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clin Cardiol 2014;37:131-9. [PMID: 24477778 DOI: 10.1002/clc.22248] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
329 Larosa JC. Treatment of Cholesterol in the Elderly: Statins and Beyond. Curr Atheroscler Rep 2014;16. [DOI: 10.1007/s11883-013-0385-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
330 Hassan M, Yacoub M. GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum. Glob Cardiol Sci Pract 2014;2014:360-6. [PMID: 25780789 DOI: 10.5339/gcsp.2014.49] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
331 Guyton JR, Campbell KB, Lakey WC. Statin intolerance: more questions than answers. Expert Rev Clin Pharmacol 2014;7:1-3. [PMID: 24308790 DOI: 10.1586/17512433.2014.857601] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
332 Tremblay M, Bouhali T, Gaudet D, Brisson D. Genealogical analysis as a new approach for the investigation of drug intolerance heritability. Eur J Hum Genet 2014;22:916-22. [PMID: 24281370 DOI: 10.1038/ejhg.2013.270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
333 Giugliano RP, Braunwald E. The year in acute coronary syndrome. J Am Coll Cardiol. 2014;63:201-214. [PMID: 24239661 DOI: 10.1016/j.jacc.2013.10.041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
334 Mancini GB, Tashakkor AY, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng DS, Pearson GJ, Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013;29:1553-68. [PMID: 24267801 DOI: 10.1016/j.cjca.2013.09.023] [Cited by in Crossref: 110] [Cited by in F6Publishing: 112] [Article Influence: 12.2] [Reference Citation Analysis]
335 Mampuya WM, Frid D, Rocco M, Huang J, Brennan DM, Hazen SL, Cho L. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 2013;166:597-603. [PMID: 24016512 DOI: 10.1016/j.ahj.2013.06.004] [Cited by in Crossref: 130] [Cited by in F6Publishing: 118] [Article Influence: 14.4] [Reference Citation Analysis]